The Nomination Committee's proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019
Oasmia's Nomination Committee has informed the company of its proposal regarding Board of Directors and auditor ahead of the Annual General Meeting September 26, 2019.
The Nomination Committee proposes Hege Hellström and Anders Härfstrand as new board members. In addition, the nomination committee proposes re-election of the current Board members Jörgen Olsson, Peter Zonabend, Gunilla Öhman and Sven Rohmann. Jörgen Olsson is proposed to be re-elected as Chairman of the Board.
Hege Hellström has worked at the biotechnology company Sobi since 2013 and was president for EMENAR (Europe, Middle East, North Africa and Russia). Prior to that, she was globally responsible for the Cardiovascular business area within Sanofi, VP Renal Europe and Head of Regional Liaisons, Sanofi, VP Renal and Endocrine Europe, Genzyme, General Manager Benelux Genzyme. Before Genzyme, she was 13 years at Baxter. Hege Hellström is 54 years old and has a degree in Bioengineering from Ullevaal School of Bioengineering, Oslo, Norway and marketing and finance education at BI, Norwegian Business School.
Anders Härfstrand has been an advisor within the pharmaceutical industry since 2015 and a board member of both private and listed companies in the sector (present NASDAQ-listed Prothena). Prior to that, he has held leading positions in a number of successful biotechnology companies and has long experience in building global commercial operations with billion-dollar turnover, driving organic growth, restructuring and mergers. He has been CEO of a number of companies, including Nitec Pharma AG, Humabs Biomed SA, ADAMA AGRO (CHEM CHINA) and BBB Therapeutics. Before that, he held leading world wide roles within Serono, Pfizer and Pharmacia. Anders Härfstrand is 63 years old and has a MD and Ph.D at Karolinska Institutet in Stockholm.
The Nomination Committee proposes that the registered audit firm KPMG be elected as new auditor. KPMG has informed the nomination committee that the authorized auditor Duane Swanson will be the Lead Audit Partner if KPMG is elected as auditor.
Oasmia's Nomination Committee consists of Per Arwidsson (Arwidsro), the Chairman of the Nomination Committee, Håkan Lagerberg and Jörgen Olsson, Chairman of the Board.
The Annual General Meeting will take place on Thursday, September 26, 2019 at 2:00 pm at the company's premises in Uppsala.
For more information:
Investor Relations Oasmia
E-mail: IR@oasmia.com
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nokia Corporation: Repurchase of own shares on 17.04.202417.4.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 17 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 17.04.2024 Espoo, Finland – On 17 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL547,2403.16CEUX--BATE--AQEU--TQEX--Total547,2403.16 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of
Referat af ordinær generalforsamling17.4.2024 20:13:49 CEST | pressemeddelelse
Den 17. april 2024 blev der afholdt ordinær generalforsamling i Fast Ejendom Danmark A/S, CVR-nr. 28 50 09 71, hos Accura Advokatpartnerselskab, Alexandriagade 8, 2150 Nordhavn. Dagsorden 1. Valg af dirigent 2. Bestyrelsens beretning for regnskabsåret 2023 3. Fremlæggelse af årsrapport 2023 til godkendelse og forslag til resultatets anvendelse 4. Meddelelse af decharge til bestyrelsen og direktionen 5. Resultat af bestyrelsesevaluering 6. Fremlæggelse af vederlagspolitik til godkendelse 7. Præsentation af og vejledende afstemning om vederlagsrapporten 8. Godkendelse af vederlag til bestyrelsen for 2024 9. Valg af medlemmer til bestyrelsen 9a) Udvidelse af bestyrelsen fra 3 til 4 medlemmer 9b) Valg af medlemmer til bestyrelsen 10. Valg af revisor 11. Forslag fra bestyrelse eller aktionærer 11a) Bemyndigelse til bestyrelsen til at forhøje kapitalen ved kontant kapitalforhøjelse 11b) Bemyndigelse til bestyrelsen til at udstede konvertible gældsbreve 12. Bemyndigelse til generalforsamlinge
Grant of Incentive Subscription Rights in IDEX Biometrics 17 April 202417.4.2024 20:00:00 CEST | Press release
The board of directors of IDEX Biometrics ASA resolved on 17 April 2024 to issue 550,000 incentive subscription rights to employees in the IDEX Biometrics group. The grant was made under the company's 2023 incentive subscription rights plan as amended at the extraordinary general meeting on 21 December 2023. The exercise price of the subscription rights is NOK 0.15 per share and the SRs vest by 50% per year over two years. The SRs expire on 23 May 2028. Following the grant there are 18,023,725 subscription rights outstanding in IDEX Biometrics. Primary insiders IDEX discloses transactions by the following primary insider, who were granted incentive subscription rights (SRs) to IDEX shares ISIN NO0013107490: – CEO Vince Graziani was granted 250,000 SRs at NOK 0.15 per share – CTO Anthony Eaton was granted 150,000 SRs at NOK 0.15 per share – CCO Catharina Eklof was granted 150,000 SRs at NOK 0.15 per share For further information contact: Marianne Bøe, Head of Investor Relations E-mail:
Reykjavík Energy | Green Bond Auction Results17.4.2024 19:59:49 CEST | Press release
Today, April 17th, 2024, Reykjavík Energy (RE; Orkuveita Reykjavíkur) concluded a green bond auction in the green bond classes OR020934 GB and OR180255 GB. OR020934 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of September 2nd, 2034. Previously, bonds have been issued in the category with a nominal value of ISK 22,482 million. The series attracted bids totaling ISK 1,980 million nominal value at yields between 3.95-4.08%. OR accepted bids amounting to ISK 1,780 million at a yield of 4,02%. OR180255 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of February 18th, 2055. Previously, bonds in the category have been issued with a nominal value of ISK 30,521 million. The series attracted bids totaling ISK 1,315 million nominal value at yields between 3.40 -3.52%. OR accepted bids amounting to ISK 1,215 million at a yield of 3,50%. Fossar Investment Bank oversees the issuance and sale o
TGS and PGS Receive Norwegian Competition Clearance for Merger17.4.2024 19:15:00 CEST | Press release
OSLO, Norway (17 April 2024) - Reference is made to the joint stock exchange announcement on 18 September 2023 by TGS ASA ("TGS" or the "Company," OSE: TGS) and PGS ASA ("PGS," OSE: PGS) regarding the combination of the two companies (the "Merger") to establish the premier energy data company, as well as subsequent announcements on 25 October 2023 and 1 December 2023 regarding, respectively, the execution of the definitive merger agreement and approval by the extraordinary general meetings. As further announced in the update on 14 February 2024, the Merger has been subject to review by the competition authorities in the UK as well as in Norway. With respect to Norway, TGS and PGS are pleased to confirm that the Norwegian Competition Authority (the "NCA") today has provided its clearance of the Merger. With respect to the UK, the UK Competition Market Authority (the "CMA") is still in its phase I review. The deadline for the CMA to announce clearance or phase II review is 11 June 2024.